As of August 9, 2023, a variety of analysts have shared their insights on Revance Therapeutics (NASDAQ: RVNC) stock over the past 3 months. In terms of ratings, three analysts have suggested a hold rating for Revance Therapeutics, while six analysts have expressed a buy rating. Further analysis reveals that seven Wall Street analysts have provided 12-month price targets for Revance Therapeutics within the same time frame. RVNC Stock Analysis: Promising Performance and Positive Outlook for Revance Therapeutics IncRVNC stock had a promising performance on August 9, 2023, with a median target price of $42.00 and a buy rating from analysts. Revance Therapeutics Inc is scheduled to release its next earnings report on November 7, which may impact the stock’s future trajectory.

Source: Wall Street Journal August 09, 2023 13:58 UTC